Control-IQ Technology in Individuals With Type 2 Diabetes

Exclusion Criteria

• •Prior use of Tandem t:slim X2 insulin pump with Control-IQ technology
• •Two or more episodes of severe hypoglycemia (needing assistance) in the past 6 months
• •History of inpatient psychiatric treatment in the past 6 months
• •History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to screening or unwillingness to agree to abstain from illicit drugs throughout the study.
• •History of significant heart disease, lung disease, liver disease, chronic kidney disease, or other systemic disease determined by investigator to interfere with the study, or make required exercise unsafe
• •History of significant vision, hearing, or dexterity problems that will impair use of the closed loop system
• •Use of glucocorticoids, beta blockers, sulfonylureas, meglitinides or other medications specifically listed in the protocol or determined by investigator to interfere with the study
• •Unstable dose of SGLT-2 inhibitor, GLP-1 receptor agonist, or other adjuvant medication specifically listed in the protocol, or starting a new glucose lowering agent during the trial.
• •Unstable dose of any medication used for weight loss, as listed in the protocol, or starting a new medication for weight loss during the trial.
• •Abnormal screening electrocardiogram consistent with increased risk during exercise, such as arrhythmia, ischemia, or prolonged QTc interval (\>450 ms)
• •History of hemodialysis
• •History of adrenal insufficiency
• •Uncontrolled hypo- or hyperthyroidism
• •Significant diabetes related complications, based on investigator assessment
• •Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is an investigative site personnel directly affiliated with this study or who is an employee of Tandem Diabetes Care, Inc.